TY - JOUR
T1 - Antivascular endothelial growth factor agents for wet age-related macular degeneration
T2 - an IRIS registry analysis
AU - MacCumber, Mathew W.
AU - Yu, Justin S.
AU - Sagkriotis, Alexandros
AU - B, Guruprasad
AU - Burugapalli, Bhavya
AU - Bi, Xiaoyu
AU - Agashivala, Neetu
AU - Wykoff, Charles C.
N1 - Funding Information:
The authors have made the following disclosures: Dr. Mathew MacCumber is an owner/partner at Illinois Retina Associates, S.C. a Professor in the Department of Ophthalmology at Rush University Medical Center, Chicago, Illinois, and a consultant for Novartis, Regeneron, Genentech, and Allergan. Justin Yu, Neetu Agashivala, and Guruprasad B are employees of Novartis Pharmaceuticals Corporation, East Hanover, NJ. Alexandros Sagkriotis is an employee of Novartis Pharma AG, Basel, Switzerland. Bhavya Burugapalli and Xiaoyu Bi are former employees of Verana Health, a consulting company to Novartis. Dr. Charles Wykoff is a partner at Retina Consultants of Houston and Retina Consultants of America; is affiliated with Blanton Eye Institute, Houston Methodist Hospital & Weill Cornell Medical College, Houston, Tex.; and is a consultant for and receives research grants from Bayer, Novartis, Genentech, Roche, Regeneron. Write All, Inc. assisted in content development and received funding from Novartis for its contributions. The study was sponsored by Novartis Pharmaceuticals Corporation. The sponsor had a role in the study design, data collection, data analysis, and manuscript preparation. Part of the data in this manuscript were presented at the Retina Society Annual Meeting, London, England, September 11-15, 2019, and additional information was presented as a poster at the American Academy of Ophthalmology (Academy) Annual Meeting, San Francisco, Calif. October 12-15, 2019.
Funding Information:
The authors have made the following disclosures: Dr. Mathew MacCumber is an owner/partner at Illinois Retina Associates, S.C., a Professor in the Department of Ophthalmology at Rush University Medical Center, Chicago, Illinois, and a consultant for Novartis, Regeneron, Genentech, and Allergan. Justin Yu, Neetu Agashivala, and Guruprasad B are employees of Novartis Pharmaceuticals Corporation, East Hanover, NJ. Alexandros Sagkriotis is an employee of Novartis Pharma AG, Basel, Switzerland. Bhavya Burugapalli and Xiaoyu Bi are former employees of Verana Health, a consulting company to Novartis. Dr. Charles Wykoff is a partner at Retina Consultants of Houston and Retina Consultants of America; is affiliated with Blanton Eye Institute, Houston Methodist Hospital & Weill Cornell Medical College, Houston, Tex.; and is a consultant for and receives research grants from Bayer, Novartis, Genentech, Roche, Regeneron. Write All, Inc. assisted in content development and received funding from Novartis for its contributions.
Publisher Copyright:
© 2021 Canadian Ophthalmological Society
PY - 2023/6
Y1 - 2023/6
N2 - OBJECTIVE: To evaluate treatment patterns and outcomes of patients in the United States who received antivascular endothelial growth factor (anti-VEGF) agents for wet age-related macular degeneration (AMD).DESIGN: Retrospective study PARTICIPANTS: Patients with wet AMD.METHODS: Using the Intelligent Research in Sight Registry, we studied patients with wet AMD who received ≥1 anti-VEGF injection, who were ≥50 years old, and with ≥1.5 years of follow-up. Patients were grouped based on follow-up duration (in years): ≥1.5 (cohort 1), ≥2.5 (cohort 2), and ≥3.5 (cohort 3).RESULTS: Patient characteristics were similar between treatment groups. 36.8%, 34.5%, and 39.2% of ranibizumab, aflibercept, and all anti-VEGF eyes, respectively, had an injection interval <8 weeks in length at the end of year 1. Results were similar at year 2 and 3. In cohorts 1-3, visual acuity (VA) changes from baseline ranged from 0.3 to 0.7 (year 1), -1.3 to -1.7 (year 2), and -2.8 to -3.1 (year 3) Early Treatment Diabetic Retinopathy Study letters. By the end of year 3, 41%, 39%, and 42% of ranibizumab, aflibercept, and all anti-VEGF eyes, respectively, had discontinued treatment (no injection for >6 months).CONCLUSION: Approximately one-third of eyes had injection intervals <8 weeks in length at the end of year 1. VA was slightly better at the end of year 1 and declined after the first year despite treatment. By the end of year 3, more than one-third of eyes had discontinued treatment. Given the high treatment burden, wet AMD patients may benefit from more durable approaches that require less frequent dosing.
AB - OBJECTIVE: To evaluate treatment patterns and outcomes of patients in the United States who received antivascular endothelial growth factor (anti-VEGF) agents for wet age-related macular degeneration (AMD).DESIGN: Retrospective study PARTICIPANTS: Patients with wet AMD.METHODS: Using the Intelligent Research in Sight Registry, we studied patients with wet AMD who received ≥1 anti-VEGF injection, who were ≥50 years old, and with ≥1.5 years of follow-up. Patients were grouped based on follow-up duration (in years): ≥1.5 (cohort 1), ≥2.5 (cohort 2), and ≥3.5 (cohort 3).RESULTS: Patient characteristics were similar between treatment groups. 36.8%, 34.5%, and 39.2% of ranibizumab, aflibercept, and all anti-VEGF eyes, respectively, had an injection interval <8 weeks in length at the end of year 1. Results were similar at year 2 and 3. In cohorts 1-3, visual acuity (VA) changes from baseline ranged from 0.3 to 0.7 (year 1), -1.3 to -1.7 (year 2), and -2.8 to -3.1 (year 3) Early Treatment Diabetic Retinopathy Study letters. By the end of year 3, 41%, 39%, and 42% of ranibizumab, aflibercept, and all anti-VEGF eyes, respectively, had discontinued treatment (no injection for >6 months).CONCLUSION: Approximately one-third of eyes had injection intervals <8 weeks in length at the end of year 1. VA was slightly better at the end of year 1 and declined after the first year despite treatment. By the end of year 3, more than one-third of eyes had discontinued treatment. Given the high treatment burden, wet AMD patients may benefit from more durable approaches that require less frequent dosing.
KW - Humans
KW - Middle Aged
KW - Ranibizumab/therapeutic use
KW - Angiogenesis Inhibitors/therapeutic use
KW - Endothelial Growth Factors/therapeutic use
KW - Vascular Endothelial Growth Factor A
KW - Retrospective Studies
KW - Intravitreal Injections
KW - Wet Macular Degeneration/diagnosis
KW - Receptors, Vascular Endothelial Growth Factor
KW - Registries
KW - Recombinant Fusion Proteins
UR - http://www.scopus.com/inward/record.url?scp=85121929660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121929660&partnerID=8YFLogxK
U2 - 10.1016/j.jcjo.2021.10.008
DO - 10.1016/j.jcjo.2021.10.008
M3 - Article
C2 - 34863677
AN - SCOPUS:85121929660
SN - 0008-4182
VL - 58
SP - 252
EP - 261
JO - Canadian Journal of Ophthalmology
JF - Canadian Journal of Ophthalmology
IS - 3
ER -